Management of localized gastric cancer

Journal of Surgical Oncology

Volumn 107, Issue 3, 2013, Pages 265-270

  Blum, Mariela A ^a   Takashi, Taketa ^a   Suzuki, Akihiro ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

D2 gastrectomy; gastric adenocarcinoma; localized gastric cancer

Indexed keywords

CAPECITABINE; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; SEMUSTINE; UFT;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVOR; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; GASTRECTOMY; GENETIC PREDISPOSITION; HELICOBACTER PYLORI; HUMAN; LYMPH NODE DISSECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; STOMACH CANCER; TREATMENT RESPONSE;

DISEASE MANAGEMENT; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; STOMACH NEOPLASMS;

EID: 84873408299     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23183     Document Type: Review

References (57)

1. Jemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. American Cancer Society: Cancer facts and figures 2012. Atlanta, GA: American Cancer Society; 2012; Available online Exit Disclaimer. Last accessed January 5, 2012.
3. Blot WJ, Devesa SS, Kneller RW, et al.: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289.
4. Parfitt JR, Miladinovic Z, Driman DK,: Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada-An epidemiological study from 1964-2002. Can J Gastroenterol 2006; 20: 271-276.
5. Lagergren J, Bergström R, Nyrén O,: Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-890.
6. Li SD, Mobarhan S,: Association between body mass index and adenocarcinoma of the esophagus and gastric cardia. Nutr Rev 2000; 58: 54-56.
7. Chow WH, Blot WJ, Vaughan TL, et al.: Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 150-155.
8. Howlader N, Noone A, Krapcho M, et al. (eds): SEER cancer statistics review, 1975-2008, Bethesda, MD: National Cancer Institute. http://seer.cancer. gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
9. Lauren P,: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
10. D'Elia L, Rossi G, Ippolito R, et al.: Habitual salt intake and risk of gastric cancer: A meta-analysis of prospective studies. Clin Nutr Edinb Scotland 2012; 31: 489-498. DOI: 10.1016/j.clnu.2012.01.003. Epub 2012 Jan 31. Review.
11. Liu C, Russell RM,: Nutrition and gastric cancer risk: An update. Nutr Rev 2008; 66: 237-249.
12. Gammon MD, Schoenberg JB, Ahsan H, et al.: Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89: 1277-1284.
13. Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789.
14. Brown LM,: Helicobacter pylori: Epidemiology and routes of transmission. Epidemiol Rev 2000; 22: 283-297.
15. Crew KD, Neugut AI,: Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362.
16. Ushijima T, Hattori N,: Molecular pathways: Involvement of helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res 2012; 18: 923-929.
17. Masciari S, Dewanwala A, Stoffel EM, et al.: Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011; 13: 651-657.
18. Lynch HT, Lynch JF, Shaw TG,: Hereditary gastrointestinal cancer syndromes. Gastrointest Cancer Res 2011; 4: S9-S17.
19. Hofgärtner WT, Thorp M, Ramus MW, et al.: Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol 1999; 94: 2275-2281.
20. Pagon RARA, Bird TDTD, Dolan CRCR, et al. (eds): GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle, [cited 2012 Mar 16]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20301443, 1993
21. Guilford P, Humar B, Blair V,: Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010; 13: 1-10.
22. Kluijt I, Sijmons RH, Hoogerbrugge N, et al.: Familial gastric cancer: Guidelines for diagnosis, treatment and periodic surveillance. Famil Cancer 2012; 11: 363-369. DOI: 10.1007/s10689-012-9521-y.
23. Adachi Y, Sakino I, Matsumata T, et al.: Preoperative assessment of advanced gastric carcinoma using computed tomography. Am J Gastroenterol 1997; 92: 872-875.
24. Räsänen JV, Sihvo EIT, Knuuti MJ, et al.: Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10: 954-960.
25. Edge SB,: Cancer AJC on: AJCC cancer staging handbook: From the AJCC cancer staging manual. Springe, New York Dordrecht Heidelberg London: Springer; 2010.
26. Ajani JA, Barthel JS, Bekaii-Saab T, et al.: Gastric cancer. J Natl Compr Canc Netw 2010; 8: 378-409.
27. Japanese Gastric Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112. DOI: 10.1007/s10120-011-0041-5.
28. Schuhmacher C, Gretschel S, Lordick F, et al.: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218.
29. Ychou M, Boige V, Pignon J-P, et al.: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721.
30. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
31. Hartgrink HH, van de Velde CJH, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30: 643-649.
32. Nio Y, Koike M, Omori H, et al.: A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer-A single institute study. Anticancer Res 2004; 24: 1879-1887.
33. Kobayashi T, Kimura T,: [Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer]. Gan To Kagaku Ryoho 2000; 27: 1521-1526.
34. Ajani JA, Winter K, Okawara GS, et al.: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24: 3953-3958.
35. Ajani JA, Mansfield PF, Crane CH, et al.: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23: 1237-1244.
36. Ajani JA, Mansfield PF, Janjan N, et al.: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22: 2774-2780.
37. Paoletti X, Oba K, Burzykowski T, et al.: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-1737.
38. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
39. Sasako M, Sakuramoto S, Katai H, et al.: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol Off J Am Soc Clin Oncol 2011; 29: 4387-4393. DOI: 10.1200/JCO.2011.36.5908. Epub 2011 Oct 17.
40. Bang Y-J, Kim Y-W, Yang H-K, et al.: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321. DOI: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7.
41. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
42. Kim S, Lim DH, Lee J, et al.: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005; 63: 1279-1285.
43. Lee J, Lim DH, Kim S, et al.: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273.
44. Engstrom PF, Lavin PT, Douglass HO Jr, et al.: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985; 55: 1868-1873.
45. Coombes RC, Schein PS, Chilvers CE, et al.: A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 1990; 8: 1362-1369.
46. Krook JE, O'Connell MJ, Wieand HS, et al.: A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-2458.
47. Grau JJ, Estapé J, Alcobendas F, et al.: Positive results of adjuvant mitomycin-C in resected gastric cancer: A randomised trial on 134 patients. Eur J Cancer 1993; 29A: 340-342.
48. Macdonald JS, Fleming TR, Peterson RF, et al.: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494.
49. Lise M, Nitti D, Marchet A, et al.: Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763.
50. Tsavaris N, Tentas K, Kosmidis P, et al.: A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 1996; 42: 220-226.
51. Nakajima T, Nashimoto A, Kitamura M, et al.: Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: A randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999; 354: 273-277.
52. Bajetta E, Buzzoni R, Mariani L, et al.: Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
53. Nashimoto A, Nakajima T, Furukawa H, et al.: Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003; 21: 2282-2287.
54. Popiela T, Kulig J, Czupryna A, et al.: Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer 2004; 7: 240-245.
55. Bouché O, Ychou M, Burtin P, et al.: Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16: 1488-1497.
56. Nitti D, Wils J, Dos Santos JG, et al.: Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 2006; 17: 262-269.
57. Nakajima T, Kinoshita T, Nashimoto A, et al.: Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007; 94: 1468-1476.